RE:RE:RE:RE:Where is Andrew de GuttadauroOh Canaduh, I have to admire your optimism...
How many Chief Medical Officers have we had in the past 5 years - 3 isn't it..? What did 2 of them see that made them run for the hills..?
And if Guttatdauro had left to retire, ONCY would have announced it, as many companies do with a 'thank you for your valuable contribution..."... so we can be pretty certain it's not retirement...
When the company is on the cusp of being sold for $10 Billion (thanks for the believable figure Noteable), why leave..? Is it more like pushed because of the fiasco with PanCan, and more failed expectations.
The recent deal with Anson and previous selling into rallies all tell us one thing... If you are expecting to close a deal, you don't need to stop a rally to finance operations... it's telling because everytime is the same... they are NEVER any closer to a deal, and so they sell into a rally and give themselves another year of operations. It'll be different next time, we can cure mice you know..!
I'm beginning to wonder if ONCY will even survive 2024. 25 years, 1 ex lying CEO who had penchant for nepotism, multiple failed Phase II's, years of delayed trial results, business partnerships that vanish (anyone recall reading of the dissolution of the Celgene partnership??), Adlai Nortye, the closest they have to a partner has all the data it needs to run a phase III, but yet removed Pela from it's pipeline slides...
A failed PH.III in H&N (where patients with fever (a sign the virus is working) were withdrawn making the data a hodgepodge of claims... a successful Phase II in mBC that was rewarded with a SPA and a green light from the FDA to go ahead and run a Phase III, but no... they include a CPI they later reveal was kinda expected not to work, repeat data from that reproduce IND-213 but which with too few patients to for statistical relevance and they wonder why there is no partner to be found.
"we're in discussions... " and this has been the same mantra for 10 years...
They had a partner for a Pancreatic Phase III, who abandons them without let or hindrance from the company... By their own admission, without PanCan, the Ph III for this will cost 80 million, and ONCY has 26 million of cash... Go figure how they'll manage that.
As for running a Phase III in mBC, had they started this in 2018 when they had the opportunity, it would be in submission to FDA by now... and they could then use income to run against a basked of CPIs.
Roche - as per Matts own words, all Roche needs to pull the trigger is the Aware-1 data.. roll on another three years (for a trial Matt told us would take a few months), and Roche has not pulled any triggers.
Now there may not even be a market if the ADACs are successful... bear in mind folks that IND-213 started 11 years ago, and they still use that data from that trial in their slide pack, as though it is new
FFS Matt, please fire yourself and sell up... your promises are poison. Shold I mention the fabled biomarker. It's affirmed by two trials, but they can't use 'confirmed', because it ain't.
And you think Guttadauro's departure may portend good news... man I want what you is smoking, cause you is defo on a high.